Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis

Semin Dial. 2012 Mar-Apr;25(2):233-8. doi: 10.1111/j.1525-139X.2011.00951.x. Epub 2011 Sep 15.

Abstract

Catheter-related blood stream infections may be reduced by interdialytic locking with Taurolidine, a nontoxic antimicrobial agent. A formulation of 1.35% Taurolidine in 4% citrate (TC) is associated with a greater need for thrombolysis to maintain catheter patency than 5000 U/ml heparin. Our aim was to determine whether addition of 500 Units/ml of heparin to TC reduces the need for thrombolysis. TCH (1.35% taurolidine, 4% citrate and 500 U/ml heparin) was compared to TC and Heparin 5000 U/ml using retrospective data. Hundred and six adult hemodialysis patients with internal jugular tunnelled intravascular catheters using TCH were compared with 34 patients using TC and 34 patients using heparin 5000 U/ml respectively. Outcomes were time to first use of thrombolysis and bacteremia rates.TCH reduced the need for thrombolysis compared to TC (hazard ratio, 0.2; 95%CI: 0.06, 0.5; p < 0.001) and was not significantly different from heparin 5000 U/ml (hazard ratio, 1.4; 95%CI: 0.5, 3.9; p = 0.5). The bacteremia rates from all causes were 1.33, 1.22 and 3.25 per 1000 catheter- days (p < 0.001) in the TCH, TC and heparin groups respectively. Addition of 500 U/ml heparin to TC reduces the need for thrombolysis without increasing bacteremia and may achieve patency comparable to heparin 5000 U/ml.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Anti-Infective Agents / therapeutic use
  • Anticoagulants / therapeutic use
  • Bacteremia / drug therapy*
  • Bacteremia / etiology
  • Catheter-Related Infections / drug therapy*
  • Catheter-Related Infections / epidemiology
  • Catheter-Related Infections / prevention & control
  • Catheters, Indwelling / adverse effects
  • Catheters, Indwelling / microbiology
  • Citric Acid / therapeutic use
  • Double-Blind Method
  • Drug Therapy, Combination
  • Equipment Contamination / prevention & control
  • Female
  • Follow-Up Studies
  • Heparin / therapeutic use*
  • Humans
  • Incidence
  • Kaplan-Meier Estimate
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / therapy
  • Linear Models
  • Male
  • Middle Aged
  • Needs Assessment
  • Proportional Hazards Models
  • Renal Dialysis / adverse effects
  • Renal Dialysis / methods*
  • Risk Assessment
  • Taurine / analogs & derivatives*
  • Taurine / therapeutic use
  • Thiadiazines / therapeutic use*
  • Thrombolytic Therapy / methods*
  • Treatment Outcome
  • Vascular Patency / physiology

Substances

  • Anti-Infective Agents
  • Anticoagulants
  • Thiadiazines
  • Taurine
  • Citric Acid
  • taurolidine
  • Heparin